The MiR-200 Family Controls Beta-tubulin III Expression and is Associated with Paclitaxel-based Treatment Response and Progression-free Survival in Ovarian Cancer Patients
Overview
Oncology
Authors
Affiliations
Ovarian cancer remains one of the leading causes of cancer deaths. Thus, new biomarkers predictive of response to the standard paclitaxel-carboplatin treatment are needed to improve chemotherapy strategies. MicroRNAs have the potential to modify drug outcomes. Based on this, we have demonstrated in this study that patients with a high expression of the miR-200 family show low levels of β-tubulin class III in ovarian carcinoma. In addition, we have established the clinical relevance of these microRNAs for ovarian cancer patients' treatment response and survival. In a well-characterized series of 72 ovarian carcinomas, the expressions of miR-141, miR-200a, miR-200b, miR-200c, and miR-429 were quantified by quantitative reverse transcription-PCR, and the protein content of β-tubulin isotypes I, II, and III was determined by immunohistochemistry. The relationship between these microRNAs, β-tubulin expression, response to paclitaxel-based treatment, progression-free survival (PFS) and overall survival was determined. While isotype I had constant high levels, protein expression of β-tubulins II and III was mutually exclusive. Low tumoral miR-200 expression was significantly associated with high β-tubulin III protein content (P values range, 0.047-<0.0001), and patients without complete response (CR) had lower miR-200c levels than patients with CR (hazard ratio (HR)=1.43, 95% confidence interval (CI)=1.02-1.99, P=0.037, multivariate analysis). Additionally, low miR-200 family expression had a trend toward poor PFS (HR>2.0, P values 0.051, 0.054, and 0.079 for miR-200c, miR-141, and miR-429 respectively, multivariate analysis). In conclusion, miR-200 family members affect the final β-tubulin III protein content of ovarian carcinomas. Furthermore, these microRNAs might constitute the biomarkers of response to paclitaxel-based treatments and relapse/progression of advanced stage ovarian carcinoma patients.
MiRNA Dysregulation in Brain Injury: An Study to Clarify the Role of a MiRNA Set.
Sessa F, Pomara C, Schembari F, Esposito M, Capasso E, Pesaresi M Curr Neuropharmacol. 2024; 23(2):209-231.
PMID: 39129166 PMC: 11793054. DOI: 10.2174/1570159X22666240808124427.
Carter R, Petrik J, Moorehead R PLoS One. 2024; 19(7):e0307178.
PMID: 39028700 PMC: 11259287. DOI: 10.1371/journal.pone.0307178.
Bhadra M, Sachan M Heliyon. 2024; 10(9):e30328.
PMID: 38707279 PMC: 11068823. DOI: 10.1016/j.heliyon.2024.e30328.
Current strategies for early epithelial ovarian cancer detection using miRNA as a potential tool.
Bhadra M, Sachan M, Nara S Front Mol Biosci. 2024; 11:1361601.
PMID: 38690293 PMC: 11058280. DOI: 10.3389/fmolb.2024.1361601.
MiRNAs related in signaling pathways of women's reproductive diseases: an overview.
Bagheri M, Khansarinejad B, Mondanizadeh M, Azimi M, Alavi S Mol Biol Rep. 2024; 51(1):414.
PMID: 38472662 DOI: 10.1007/s11033-024-09357-0.